This fully-updated third edition of Scleroderma: From Pathogenesis to Comprehensive Managementbuilds upon the well-regarded approach in the previous editions to provide integrated, concise, and up-to-date synthesis of current concepts of pathogenesis and modern approaches to management of systemic sclerosis (scleroderma). With a multidisciplinary approach to comprehensive care, this book is easily accessible for health care professionals in many fields. Comprised of the authoritative work of international experts, the new edition includes extensive updated material reflecting major developments in the field. It presents a succinct and thoughtful synthesis of current pathomechanistic concepts, providing a valuable reference tool for basic and translational investigators working in the field. Scleroderma: From Pathogenesis to Comprehensive Management serves as an essential, all-inclusive and fully up to date resource for rheumatologists, pulmonologists, cardiologists, gastroenterologists, nephrologists and all those involved in the care of scleroderma patients.



Cover
Front Matter
Part I. Introduction
1. Historical Perspective of Scleroderma
Part II. Epidemiology, Genetics and Classification
2. Epidemiology, Environmental, and Infectious Risk Factors
3. Influence of Ethnicity and Sex Bias in Systemic Sclerosis
4. Genetic Factors
5. Classification and Disease Subsets in Clinical Practice
6. Clustering and Evolving Concepts for Subclassification
7. The Clinical Aspects of Autoantibodies
8. Systemic Sclerosis Overlap Syndromes
9. Juvenile Localized and Systemic Scleroderma
10. Morphea (Localized Scleroderma)
11. Scleroderma Mimics
Part III. The Biological Basis of Systemic Sclerosis
12. Introduction: The Etiopathogenesis of Systemic Sclerosis An Integrated Overview
13. Pathology of Systemic Sclerosis
14. Inflammation and Immunity in Systemic Sclerosis
15. Autoantibodies as Markers and Possible Mediators of Scleroderma Pathogenesis
16. Mechanisms of Vascular Disease
17. Biomarkers in Systemic Sclerosis
18. Cellular and Molecular Mechanisms of Fibrosis in Systemic Sclerosis
19. Overview of Animal Models
Part IV. Cardiovascular Manifestations and Management
20. Raynaud's Phenomenon, Digital Ulcers and Nailfold Capillaroscopy
21. Renal Crisis and Other Renal Manifestations
22. Cardiac Involvement: Evaluation and Management
Part V. Pulmonary Manifestations and Management
23. Overview of Lung Involvement
24. Clinical Assessment of ILD
25. Lung Imaging Perspective in Scleroderma
26. Treatment of Interstitial Lung Disease in Systemic Sclerosis
27. Pathogenesis of Pulmonary Arterial Hypertension
28. Clinical Assessment of Pulmonary Hypertension
29. The Management of Pulmonary Arterial Hypertension in the Setting of Systemic Sclerosis
Part VI. Gastrointestinal Manifestations and Management
30. Overview of Gastrointestinal Tract Involvement
31. Upper Gastrointestinal Tract: Manifestations of Systemic Sclerosis
32. Lower Gastrointestinal Tract Involvement: Understanding the Interplay of Motility, the Microbiome, and Nutrition
Part VII. Skin, Musculoskeletal and Other Complications
33. Evaluation and Management of Skin Disease
34. Calcinosis
35. Tendons, Joints, and Bone
36. Skeletal Muscle Involvement
37. Cancer in Systemic Sclerosis
38. Overlooked Manifestations
39. Pregnancy
40. Vaccinations in Patients with Systemic Sclerosis
Part VIII. Management and Outcome Assessment
41. Overview of Management and Outcome Assessment in Systemic Sclerosis
42. Management of Progressive Skin Involvement in Diffuse Scleroderma
43. Hematopoietic Stem Cell Transplantation
44. Immune-Targeted Therapies in SSc
45. Physical and Occupational Therapy
46. Psychosocial Issues and Care for Patients with Systemic Sclerosis
47. Measuring Disease Activity and Outcomes in Clinical Trials
48. Evolving Clinical Trial Design and Innovative Approaches
49. Drug Development and Regulatory Considerations for Systemic Sclerosis Therapies
Part IX. Case Studies: Approach to Complex Clinical Problems
50. Managing the Ischemic Finger in Scleroderma
51. Scleroderma Renal Crisis: A Case Study
52. Rapid Diffuse Skin Disease with Progressive Joint Contractures
53. Management of the Scleroderma Patient with Pulmonary Arterial Hypertension Failing Initial Therapy
54. Pseudo-obstruction with Malabsorption and Malnutrition
55. Progressive Interstitial Lung Disease Non-Responsive to Immunosuppressive Therapy
56. Body Image Distress in Scleroderma
57. Managing Complicated Digital Ulcers
58. Lower Limb Ulceration
Back Matter